Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Area of Science:

• Orthopedic Surgery
• Pharmacology
• Vascular Medicine

Background:

• Major knee surgery presents a high risk of venous thromboembolism (VTE) despite standard thromboprophylaxis.
• Fondaparinux, a novel synthetic antithrombotic, is investigated for its potential to mitigate VTE risk in this patient population.

Purpose of the Study:

• To compare the efficacy and safety of fondaparinux versus enoxaparin in preventing VTE after major knee surgery.
• To assess the incidence of VTE and major bleeding in patients receiving either treatment.

Main Methods:

• A double-blind study randomized 1049 patients undergoing elective major knee surgery to receive either fondaparinux (2.5 mg daily) or enoxaparin (30 mg twice daily) postoperatively.
• The primary efficacy endpoint was VTE by postoperative day 11, defined by venography, symptomatic DVT, or pulmonary embolism.
• The primary safety endpoint was major bleeding.

Main Results:

• Fondaparinux demonstrated a significantly lower VTE incidence (12.5%) by day 11 compared to enoxaparin (27.8%), a 55.2% risk reduction (P<0.001).
• Major bleeding occurred more frequently with fondaparinux (P=0.006), but no significant differences were observed in fatal bleeding, reoperation due to bleeding, or critical organ bleeding.

Conclusions:

• Postoperative fondaparinux (2.5 mg daily) is significantly more effective than enoxaparin (30 mg twice daily) in preventing deep-vein thrombosis after major knee surgery.
• Fondaparinux offers a superior prophylactic option for VTE in this surgical context, with careful consideration of bleeding risk.